3000+ Courses from California Community Colleges

Class Central is learner-supported. When you buy through links on our site, we may earn an affiliate commission.

YouTube

Advances in Inflammatory Bowel Disease

Mary Greeley Medical Center via YouTube

Start learning Write review

Overview

Explore advances in inflammatory bowel disease (IBD) management through this comprehensive grand rounds presentation by Dr. Edward Loftus, Jr. from Mayo Clinic's Gastroenterology/Hepatology department. Delve into the changing geographic distribution of IBD, main susceptibility genes for Crohn's disease, and microbial diversity. Learn about treatment strategies for ulcerative colitis and Crohn's disease, including the efficacy of various medications such as azathioprine, infliximab, and other biologic agents. Examine factors influencing disease progression, surgical outcomes, and the importance of monitoring drug levels and antibodies in TNF antagonist therapy. Gain insights into the latest research on predictors of severe disease, mucosal healing, and pharmacokinetics of IBD treatments.

Syllabus

Intro
Changing Geographic Distribution of IBD
Main Susceptibility Genes for Crohn's Disease
Microbial Diversity in Crohn's Disease
Management of Mild to Moderate UC
Estimate of Efficacy of AZA for Treatment Success in UC Patients: Meta-Analysis
Infliximab for UC: ACT 1 and ACT 2 Clinical Remission
ACT1/2 Trials: Survival Free of Colectomy
Cyclosporine vs. Infliximab for Acute Severe UC Treatment Failure, %
Management of Crohn's Disease
Construct of Biologic Agents Used in Crohn's Disease
Induction of Clinical Remission at Week 4 In Crohn's Disease: Certolizumab, Adalimumab, Infliximab
Natalizumab (Anti-Alpha 4 Integrin) Therapy for Crohn's Disease
Baseline Factors Associated with Time to Surgery: Crohn's, Olmsted County, 1970-2004
Advances in IBD Natural History: Predictors of More Severe Disease
CT Enterography Healing: Equivalent to Mucosal Healing at Endoscopy?
TPMT Activity in 407 New Zealand Patients
Meta-Analysis: Association Between 6-TGN Levels and Clinical Remission
Effect of Trough Serum Infliximab Concentrations on Clinical Outcome at 52 Weeks
What Factors influence the Pharmacokinetics of TNF Antagonists?
Active Monitoring of Anti-TNF Levels May Ensure Durability of Response
Effect of Concomitant Azathioprine or Methotrexate on Anti-drug Antibodies

Taught by

Mary Greeley Medical Center

Reviews

Start your review of Advances in Inflammatory Bowel Disease

Start learning

Never Stop Learning.

Get personalized course recommendations, track subjects and courses with reminders, and more.

Sign up for free
Someone learning on their laptop while sitting on the floor.